Seer Inc
NASDAQ:SEER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Seer Inc
NASDAQ:SEER
|
US |
|
P
|
Plastikkart Akilli Kart Iletisim Sistemleri Sanayi ve Ticaret AS
IST:PKART.E
|
TR |
Seer Inc
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 118 full-time employees. The company went IPO on 2020-12-04. The firm enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The firm's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 118 full-time employees. The company went IPO on 2020-12-04. The firm enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The firm's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.
Revenue Growth: Seer reported Q4 revenue of $4.2 million and full-year 2025 revenue of $16.6 million, up 17% year over year, though Q4 results fell short of expectations due to ongoing funding headwinds.
Guidance: 2026 revenue is expected to be between $16 million and $18 million, with management describing the outlook as conservative given continued uncertainty around NIH and customer funding.
Profitability: Net loss narrowed to $16 million in Q4 and $73.6 million for 2025, with operating expenses down 19% year over year.
Share Repurchases: The company repurchased 5.3 million shares in 2025 and authorized an additional $25 million for repurchases, reducing outstanding shares by 13% since 2024.
Installed Base Expansion: Installed instrument base grew 67% in 2025 to 82 units, driven by initiatives to lower adoption barriers and strategic placements.
Innovation & AI: Seer highlighted significant product innovation, including new assay and instrument launches and the upcoming release of an AI-enabled data analysis suite.
Market Headwinds: Management cited persistent pressure on customer budgets, especially related to NIH funding delays, resulting in cautious guidance and lumpy revenue.
